Mature dendritic cells prime functionally superior melan-A-specific CD8+ lymphocytes as compared with nonprofessional APC

Journal of Immunology

Volumn 167, Issue 3, 2001, Pages 1188-1197

  Salio, M ^a   Shepherd, D ^a   Dunbar, P R ^a   Palmowski, M ^a   Murphy, K ^a   Wu, L ^a   Cerundolo, V ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HOMING RECEPTOR; MELAN A; PADGEM PROTEIN;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CELL FUNCTION; CELL MATURATION; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MEMORY CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0035421798     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.3.1188     Document Type: Article

References (75)

1. Cancer tumor antigens
2. A new era for cancer immunotherapy based on the genes that encode cancer antigens
3. Design and evaluation of antigen-specific vaccination strategies against cancer
4. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
5. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
6. Phenotypic analysis of antigen-specific T lymphocytes
7. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes
8. + T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals
9. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
10. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response
11. + T cells produce antiviral cytokines but are impaired in cytolytic function
12. + T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained
13. Analysis of successful immune responses in persons infected with hepatitis C virus
14. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
15. Viral immune evasion due to persistence of activated T cells without effector function
16. Dendritic cells and the control of immunity
17. Origin, maturation and antigen presenting function of dendritic cells
18. Myeloma based expression system for production of large mammalian proteins
19. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma
20. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2
21. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood
22. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor α
23. CD40 ligand-independent B cell activation revealed by CD40 ligand-deficient T cell clones: Evidence for distinct activation requirements for antibody formation and B cell proliferation
24. CCR7 Expression and memory T cell diversity in humans
25. Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas
26. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines: Fine specificity and MART-1 melanoma antigen recognition
27. Active immunotherapy with allogeneic tumor cell vaccines: Present status
28. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent Th1 polarization
29. Kinetics of dendritic cell activation: Impact on priming of Th1, Th2 and nonpolarized T cells
30. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA
31. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
32. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)
33. The interplay between the duration of TCR and cytokine signaling determines T cell polarization
34. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
35. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-AI
36. Peptide vaccination in clinical oncology
37. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12
38. Antitumor effects of interleukin-12 (IL-12): Applications for the immunotherapy and gene therapy of cancer
39. + T cells in melanoma patients receiving interleukin 12
40. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity
41. The molecular basis of allorecognition
42. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine
43. Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine
44. Immune suppression by recombinant interleukin (rIL)-12 involves intefferon γ induction of nitric oxide synthase 2 (iNOS) activity: Inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect
45. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma
46. Immunological memory and protective immunity: Understanding their relation
47. Dynamics of T lymphocyte responses: Intermediates, effectors, and memory cells
48. Faces and phases of human CD8 T-cell development
49. + T cells
50. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs
51. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
52. Expression of L-selectin on Th1 cells is regulated by IL-12
53. Human recombinant interferon-β influences T helper subset differentiation by regulating cytokine secretion pattern and expression of homing receptors
54. Metalloproteinase-mediated regulation of L-selectin levels on leukocytes
55. Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice
56. Molecular mechanisms of lymphocyte homing to peripheral lymph nodes
57. Biology of chemokine and classical chemoattractant receptors: Differential requirements for adhesion-triggering versus chemotactic responses in lymphoid cells
58. L-selectin-deficient mice have impaired leukocyte recruitment into inflammatory sites
59. Cutting edge: Identification of a novel chemokine receptor that binds dendritic cell- and T cell-active chemokines including ELC, SLC, and TECK
60. New paths in human cancer serology
61. Dendritic cells as adjuvants for immune-mediated resistance to tumors
62. The dendritic cell and human cancer vaccines
63. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
64. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
65. + melanoma patients by mature monocyte-derived dendritic cells
66. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
67. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
68. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
69. + T-cell in humans without foreign helper epitopes
70. + T cells
71. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo
72. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells
73. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells
74. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells
75. + T cells for efficient tumor cell lysis